CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Kidneys are the silent multitaskers of our body. They perform vital, behind-the-scenes work: filtering waste, balancing fluids and salts, producing hormones, and keeping our body chemistry in harmony.

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...

Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD analyses continue to support ...

OAKLAND, Calif. — Researchers have identified an approach to remove race from equations used to estimate a person’s kidney function. These equations have been criticized for potentially perpetuating ...

Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...